Welcome to LookChem.com Sign In|Join Free

CAS

  • or

131885-65-9

Post Buying Request

131885-65-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

131885-65-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 131885-65-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,8,8 and 5 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 131885-65:
(8*1)+(7*3)+(6*1)+(5*8)+(4*8)+(3*5)+(2*6)+(1*5)=139
139 % 10 = 9
So 131885-65-9 is a valid CAS Registry Number.

131885-65-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-(1H-imidazol-1-yl)-2-nitroaniline

1.2 Other means of identification

Product number -
Other names 5-imidazol-1-yl-2-nitroaniline

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:131885-65-9 SDS

131885-65-9Relevant articles and documents

Synthesis and Catalytic Applications of Heterobimetallic Carbene Complexes Obtained via Sequential Metalation of Two Bisazolium Salts

B?hmer, Maximilian,Guisado-Barrios, Gregorio,Kampert, Florian,Roelfes, Florian,Tan, Tristan Tsai Yuan,Peris, Eduardo,Hahn, F. Ekkehardt

, p. 2120 - 2131 (2019/05/21)

A simple sequential metalation approach starting from the imidazolium/benzimidazolium salt 4(I)2 yielded the heterobimetallic RhIII/M (M = PdII, IrI, AuI, RuII) complexes [6]-[9]. Alternatively, a symmetrical 1,3-imidazolium substituted benzene was used for the preparation of the heterobimetallic M′/PdII (M′ = RhIII, IrIII) complexes [12] and [13]. The versatile stepwise approach used for the preparation of complexes [6]-[9] involved the deprotonation reaction of the bisazolium salt 4(I)2 in the presence of [RhCp?(Cl)2]2 to afford the monometallic complex [5]I featuring a chelating coordinated bidentate CNHC^Cphenyl ligand. Complex [5]I was reacted with Ag2O to give a nonisolated RhIII/AgI complex which in a subsequent transmetalation reaction yielded the heterobimetallic RhIII/M bis-NHC complexes (M = PdII [6], IrI [7], AuI [8], RuII [9]). Similarly, heterobimetallic M′/PdII bis-NHC complexes [12] (M′ = RhIII) and [13] (M′ = IrIII) have been prepared from a symmetrical bisazolium salt by generating first the monometallic M′ complexes followed by a transmetalation reaction of the in situ generated M′/AgI complexes with [Pd(dmba)(μ-Cl)]2. The RhIII/PdII complexes [6] and [12] and the IrIII/PdII complex [13] were used as catalysts for two orthogonal tandem reactions, namely, the Suzuki-Miyaura coupling/transfer hydrogenation and the Suzuki-Miyaura-coupling/α-alkylation of ketones. The catalytic activity of the heterobimetallic complexes was compared to mixtures of the related monometallic analogues [14]-[17], with the heterobimetallic complexes generally showing a higher catalytic activity. In addition, nBuOH was found to play a dual role as an alkylating and reducing agent in the Suzuki-Miyaura coupling/α-alkylation of ketones.

IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

-

Page/Page column 113; 114, (2016/04/20)

The present disclosure is directed to compounds of formula (Ie) and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, m, n, X1, X2, X3 and X4 are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

Sulfonamide-based compounds as protein tyrosine kinase inhibitors

-

Page/Page column 5/16; 7; 12, (2008/06/13)

Various sulfonamide-based compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 131885-65-9